MRK News 59.92 09/15/2014 09:49:40 Merck & Company (MRK)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 59.92 $MRK

New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma
PR Newswire - 1 hr 34 mins ago
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Pharmacyclics Inc. (NASDAQ: PCYC) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6464-100free.

BeiGene Receives Clinical Milestone Payment for Development of BGB-290
Business Wire - 2 hrs 48 mins ago
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-290, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor candidate currently in Phase 1 development. The milestone triggers a US$ 9 million payment from Merck to BeiGene.

Merck Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 1:00AM CDT
Merck Millipore, the Life Science division of Merck, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.

Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.

Dow 30 Stock Roundup: Boeing Bags $11B Order, GE to Sell Appliance Unit to Electrolux - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Sep 12, 9:50AM CDT
The Dow had a dismal week as energy prices continued to dominate proceedings.

Research and Markets: Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
Business Wire - Fri Sep 12, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/572r9k/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering.

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
PR Newswire Europe - Fri Sep 12, 9:08AM CDT
DARMSTADT, Germany, September 12, 2014 /PRNewswire/ --

Global Animal Health Market 2014-2018: Key Vendors are Bayer, Elanco, Merck Animal Health, Merial and Zoetis
PR Newswire Europe - Fri Sep 12, 7:02AM CDT
DUBLIN, Sept. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jr5z25/global_animal] has announced the addition of the "Global Animal Health Market 2014-2018" [http://www.researchandmarkets.com/research/jr5z25/global_animal] report to their offering.

Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
M2 - Fri Sep 12, 6:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/69j7kn/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering. The Global Asthma Market to grow at a CAGR of 4.5% over the period 2013-2018. One trend emerging in this market is the use of combination therapies for the treatment of asthma patients. These therapies can improve patient condition in persistent asthma and act via reduction of the symptoms by controlling inflammation in the respiratory tract. According to the report, the major driving factor of this market is a rise in the prevalence of environmental pollution. Globalization and urbanization coupled with industrialization lead to an increase in environmental pollution. Further, the report states that the unknown etiology of the disease is a major challenge to the market which makes it difficult for drug manufacturers to develop a remedy. The underlying causes of asthma are not completely understood, though allergens and pollutants worsen the condition of the patient. This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma: - Bronchodilators - Leukotriene antagonists - Mast cell stabilizers - Immunosuppressants Key Vendors - AstraZeneca - F. Hoffmann-La Roche - GlaxoSmithKline - Merck - Novartis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Class of Drugs - Global Bronchodilators Market - Global Leukotriene Antagonists Market - Global Mast Cell Stabilizers Market - Global Immunosuppressants Market - Global Combination of ICS/LABA Market - Global Other Asthma Drugs Market - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/69...bal_asthma

Global Animal Vaccines Market 2014-2018: Leading Vendors are Bayer HealthCare, Elanco Animal Health, Merck Animal Health, Novartis Animal Health, Sanofi & Zoetis
M2 - Fri Sep 12, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/56q7l6/global_animal) has announced the addition of the "Global Animal Vaccines Market 2014-2018" report to their offering. The Global Animal Vaccines market to grow at a CAGR of 8.25% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Animal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various animal vaccines. In terms of vaccines types, the Global Animal Vaccines market can be segmented into six: Companion Animal Vaccines, Livestock Vaccines, Porcine Vaccines, Poultry Vaccines, Equine Vaccines, and Other Animal Vaccines. One of the major emerging trends in this market is an increase in acquisitions. Vendors have been focusing on acquisitions to increase their foothold in the market through increased investments. According to the report, one of the main drivers of this market is an increase in the prevalence of animal diseases worldwide, in both developed and developing countries. As a result, the use of animal vaccines has increased. The increasing susceptibility of animals to chronic diseases has driven the revenue growth of this market to a great extent. Further, the report states that one of the main challenges that the market faces is a rise in the maintenance costs of vaccines. Though the animal vaccines have numerous benefits, the high cost of these vaccines hinders acceptability among end-users. Key Vendors - Bayer HealthCare - Elanco Animal Health - Merck Animal Health - Novartis Animal Health - Sanofi - Zoetis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/56...bal_animal

Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jn2cxm/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Merck & Co., Inc. - AbGenomics International, Inc. - ApoPharma Inc. - Novartis AG - Pfizer Inc. - OPKO Health, Inc. - Idera Pharmaceuticals, Inc. - Almirall, S.A. - Syntrix Biosystems, Inc. - Vascular Biogenics Ltd. - Hy BioPharma Inc. - GlycoMar Limited - Convoy Therapeutics, Inc. Drug Profiles - brodalumab - ixekizumab - secukinumab - tildrakizumab - LAS-41008 - adalimumab biosimilar - baricitinib - AbGn-168H - VB-201 - lunacalcipol - aminopterin sodium - HBP-347 - orilotimod - BI-655066 - IMO-8400 - PF-04965842 - MOL-4249 - AVX-001 - AMG-811 - guselkumab - AKP-11 - cyclosporine - GLY-2028 For more information visit http://www.researchandmarkets.com/research/jn2cxm/moderate

Merck Falls 1.09% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 11, 3:39PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $59.81 to a high of $60.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $60.35 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

After Yesterday's Decline of 1.09%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:39PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $59.81 to a high of $60.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $60.35 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment, an Industrial Info News Alert
Marketwire - Thu Sep 11, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Like any long-term union, the one shared between the U.S. Northeast region, which comprises Delaware, New Jersey, New York and Pennsylvania, and the Life Science Industry is a classic example of a love/hate relationship. The Northeast region has been pummeled over the past few years with scores of pharmaceutical plants closing and lucrative jobs lost. On the other hand, the region remains a favorite for capital investment from both the private and public sectors for new and upgraded life-science manufacturing plants and research centers. Currently, there are 147 active reported projects translating to a hefty $7.8 billion in total investment value.

Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - Thu Sep 11, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint

Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a licensing deal with CURx Pharmaceuticals, under which the former's Captisol-enabled lamotrigine program will be developed and commercialized.

Pipeline Analysis of Hospital Acquired Pneumonia Drugs 2014-2020: Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix
M2 - Wed Sep 10, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r49n8b/pipeline_analysis) has announced the addition of the "Pipeline Analysis of Hospital Acquired Pneumonia Drugs - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne. Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs. Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market overview Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Valneva SE - Achaogen, Inc. - Aridis Pharmaceuticals - AstraZeneca plc - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline, Inc. - Meiji Seika Pharma Co. Ltd. - Merck & Co. Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/r4...e_analysis

Dow Component Merck (MRK) To Go Ex-dividend Tomorrow
at The Street - Wed Sep 10, 10:00AM CDT
Thursday, September 11, 2014 is the ex-dividend date for Dow component (NYSE:MRK).

Global Diclofenac Market Report 2014-2019
M2 - Wed Sep 10, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tmxmbx/global_diclofenac) has announced the addition of the "Global Diclofenac Industry Report 2014" report to their offering. The report provides an basic overview of the industry including definitions, classifications, applications and industry chain structure. The diclofenac market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Diclofenac industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-six industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The diclofenac industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Diclofenac Industry Overview - Global Diclofenac Market Status Analysis - Major Regions Diclofenac Market Status Analysis - Major Countries Diclofenac Market Status and Analysis - Major Companies Diclofenac Market Status and Analysis - Diclofenac Industry Chain and Marketing Channels Analysis - Diclofenac Industry Development Trend - Diclofenac New Project Investment Feasibility Analysis - Global Diclofenac Industry Research Conclusions Companies Mentioned - A. S. Joshi And Company - Asa Biotech - Ausun - Anyang Jiuzhou Pharmaceutical Co., Ltd. - Bayer - Cpu-Pharma - Dezhou Deyao Pharmaceutical Co.,Ltd - Hainan Poly Pharm - Istituto Biochimico Italiano Spa - Iroko - Kahan Pharmaceuticals - Merck Sharp & Dohme Corp. - Metrix Healthcare Private Limited - Novartis - Nipa Pharmaceuticals Limited - Pku Healthcare Corp.,Ltd - Pfizer - Raazee Therapeutics (Pvt) Ltd. - Simcere - Sunij - Suzhou Homesun Pharmaceutical Co.,Ltd - Sri Pharmacare - Warrant Pharmaceutical - Yung Zip Chemical Co. Limited - Yangtze River Pharmaceutical Group - Zhejiang Jinhua Conba Bio-Pharm Co.Ltd For more information visit http://www.researchandmarkets.com/research/tm...diclofenac About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring CRH Stock Performance Over Five Years and Beyond

Updated Category News Views 152

Understanding CRH's Impressive Growth CRH has displayed a remarkable performance in the stock market over the last five years, outshining many of its competitors with a 10.67% annualized return. This impressive growth translates to an average annual return of 23.49% for investors. Currently, CRH boasts a market capitalization of approximately $73.09 billion, making it a...

Continue Reading
Coordinated Care's Health Tour Expands Access Across WA

Updated Category News Views 78

A Grassroots Push for Health Equity Coordinated Care, a subsidiary of Centene Corporation, is hitting the road in Washington state. This isn't about just another healthcare campaign—you’ve got two vans, 'SeeMore' and 'Flossy', bringing essential vision and dental screenings right up to the folks who need them most. Taking Healthcare Directly to Communities Let's be...

Continue Reading
Italy's Antitrust Agency Investigates Snam-Edison Deal

Updated Category News Views 229

Investigation into the Snam and Edison Gas Storage Deal Italy's antitrust agency has recently initiated an investigation concerning the transaction between Snam and Edison involving Edison's gas storage unit. This move reflects the agency's commitment to maintaining healthy competition within the energy sector. Concerns Over Market Competition The Antitrust Authority,...

Continue Reading
Truist Financial Corporation's Quarterly Performance Insights

Updated Category News Views 240

Truist Financial's Results and Earnings Overview Truist Financial Corporation (TFC) announced its latest quarterly results, showcasing a robust financial performance that illustrates the company’s strategic focus on growth and stability. This release reflects the commitment of Truist to enhance the lives of its clients and communities by providing comprehensive...

Continue Reading
Investigation Into Possible Securities Fraud at UnitedHealth Group

Updated Category News Views 350

UnitedHealth Group Under Scrutiny for Securities Claims Ademi & Fruchter LLP has launched an investigation into potential securities fraud claims against UnitedHealth Group Incorporated (NYSE: UNH). This inquiry arises following inaccurate statements made by the company regarding its operational performance and future outlook. Investors and analysts alike express serious...

Continue Reading